• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS

Bioengineers have developed a prototype ultra-sensitive sensor

Bioengineer by Bioengineer
October 29, 2013
in NEWS
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The team, from Imperial College London, report that their visual sensor technology is ten times more sensitive than the current gold standard methods for measuring biomarkers. These indicate the onset of diseases such as prostate cancer and infection by viruses including HIV. The researchers say their sensor would benefit countries where sophisticated detection equipment is scarce, enabling cheaper and simpler detection and treatments for patients. In the study, the team tested the effectiveness of the sensor by detecting a biomarker called p24 in blood samples, which indicates HIV infection.

Molly-Stevens-006

Professor Molly Stevens, from the Departments of Materials and Bioengineering at Imperial College London, says: “It is vital that patients get periodically tested in order to assess the success of retroviral therapies and check for new cases of infection. Unfortunately, the existing gold standard detection methods can be too expensive to be implemented in parts of the world where resources are scarce. Our approach affords for improved sensitivity, does not require sophisticated instrumentation and it is ten times cheaper, which could allow more tests to be performed for better screening of many diseases.” The researchers in today’s study also tested samples for the biomarker called Prostate Specific Antigen (PSA), which is an early indicator for Prostate Cancer. The team say the sensor can also be reconfigured for other viruses and diseases where the specific biomarker is known. 

The sensor works by analysing serum, derived from blood, in a disposable container. If the result is positive for p24 or PSA, there is a reaction that generates irregular clumps of nanoparticles, which give off a distinctive blue hue in a solution inside the container. If the results are negative the nanoparticles separate into ball-like shapes, creating a reddish hue. Both reactions can be easily seen by the naked eye. The team also report that the sensor was so sensitive that it was able to detect minute levels of p24 in samples where patients had low viral loads, which could not be diagnosed using existing tests such as the Enzyme-linked Immunosorbent Assay (ELISA) test and the gold standard nucleic acid based test.

Dr Roberto de la Rica, co-author of the study from the Department of Materials at Imperial College London, adds: “We have developed a test that we hope will enable previously undetectable HIV infections and indicators of cancer to be picked up, which would mean people could be treated sooner. We also believe that this test could be significantly cheaper to administer, which could pave the way for more widespread use of HIV testing in poorer parts of the world.” The next stage of the research will see the team approaching not-for-profit global health organisations, which could provide strategic direction and funding for manufacturing and distributing the sensor to low income countries. The research was funded by the Engineering and Physical Sciences Research Council (EPSRC) and by a European Research Council (ERC) starting investigator grant. The study was also supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme.

Source: Imperial College

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Weather’s Impact on Anopheles Mosquito Populations in Lagos

August 23, 2025
Ghost Spider’s Maternal Care vs. New Fly Species

Ghost Spider’s Maternal Care vs. New Fly Species

August 23, 2025

DWI-Guided vs. MRI-Based IMRT in Head & Neck

August 23, 2025

Uncovering Cutaneous SCC Genomic Diversity via Single-Cell DNA

August 23, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Weather’s Impact on Anopheles Mosquito Populations in Lagos

Ghost Spider’s Maternal Care vs. New Fly Species

DWI-Guided vs. MRI-Based IMRT in Head & Neck

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.